Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Dectin-1 Signaling Mechanisms

Award Number: R01AI071116
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2008
PERIOD OF PERFORMANCE END DATE: 05/31/2025

Group Awards By:

View Award Description

Dectin-1 Signaling Mechanisms - SUMMARY/ABSTRACT Dectin-1 is an innate immune receptor expressed by myeloid phagocytes such as macrophages and dendritic cells that is essential for effective host defense against fungal infections. Dectin-1 recognizes the β-1,3-glucan polysaccharide that makes up as much as half the dry weight of fungal cell walls, and activation of the receptor triggers phagocytosis, production of microbicidal reactive oxygen species, and production of a host of pro- inflammatory cytokines. Dectin-1 is one of only a few receptors so far shown to be sufficient for triggering phagocytosis, and it has thus become an important model for understanding how such receptors work. This renewal project focuses on further understanding the mechanisms of Dectin-1 signaling. Previous studies have documented that Dectin-1 signaling in response to common yeast such as Candida albicans promotes IL-23 production by dendritic cells that, together with other inflammatory mediators, supports a good Th1/Th17 T cell response. This response is essential for mucosal immunity to fungal infections. In contrast, we now observe that C. albicans hyphae activate dendritic cells to drive a response better characterized as Th2/Th9 and that Dectin- 1 is also critical for this response. Further, we note that colonization with certain fungi including Candida spp. and Wallemia spp. exacerbate Th2/9-driven mouse models of allergic airway disease. In this project, we will investigate the mechanisms by which the Dectin-1 signaling pathway promotes Th2 and Th9 type immune responses in vitro and in vivo. We will further develop novel strategies for pharmacologically manipulating this signaling pathway.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	14	9/15/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $533,266 )
2023	2023	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	14	5/23/2023	NON-COMPETING CONTINUATION	$533,266
														Subtotal = $533,266

Issue Date FY: 2022 ( Subtotal = $533,266 )
2022	2022	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	13	5/27/2022	NON-COMPETING CONTINUATION	$533,266
														Subtotal = $533,266

Issue Date FY: 2021 ( Subtotal = $533,266 )
2021	2021	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	12	5/21/2021	NON-COMPETING CONTINUATION	$533,266
														Subtotal = $533,266

Issue Date FY: 2020 ( Subtotal = $533,266 )
2020	2020	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	11	5/11/2020	NON-COMPETING CONTINUATION	$533,266
														Subtotal = $533,266

Issue Date FY: 2019 ( Subtotal = $533,266 )
2019	2019	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	001	10	6/12/2019	COMPETING CONTINUATION	$533,266
2019	2019	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	002	10	6/24/2019	COMPETING CONTINUATION	$0
2019	2017	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	9	11/27/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $533,266

Issue Date FY: 2017 ( Subtotal = $425,000 )
2017	2017	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	9	6/16/2017	NON-COMPETING CONTINUATION	$425,000
														Subtotal = $425,000

Issue Date FY: 2016 ( Subtotal = $425,000 )
2016	2016	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	8	6/21/2016	NON-COMPETING CONTINUATION	$425,000
														Subtotal = $425,000

Issue Date FY: 2015 ( Subtotal = $425,000 )
2015	2015	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	7	6/30/2015	NON-COMPETING CONTINUATION	$425,000
														Subtotal = $425,000

Issue Date FY: 2014 ( Subtotal = $425,000 )
2014	2014	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	6	7/15/2014	COMPETING CONTINUATION	$425,000
														Subtotal = $425,000

Issue Date FY: 2012 ( Subtotal = $389,590 )
2012	2012	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	5	1/26/2012	NON-COMPETING CONTINUATION	$389,590
														Subtotal = $389,590

Issue Date FY: 2011 ( Subtotal = $389,590 )
2011	2011	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	001	4	6/7/2011	NON-COMPETING CONTINUATION	$35,417
2011	2011	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	4	12/13/2010	NON-COMPETING CONTINUATION	$354,173
														Subtotal = $389,590

Issue Date FY: 2010 ( Subtotal = $393,525 )
2010	2010	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	3	12/10/2009	NON-COMPETING CONTINUATION	$357,750
2010	2010	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	001	3	5/28/2010	NON-COMPETING CONTINUATION	$35,775
														Subtotal = $393,525

Issue Date FY: 2009 ( Subtotal = $397,500 )
2009	2009	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	001	2	6/9/2009	NON-COMPETING CONTINUATION	$39,750
2009	2009	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	2	12/17/2008	NON-COMPETING CONTINUATION	$357,750
														Subtotal = $397,500

Issue Date FY: 2008 ( Subtotal = $397,500 )
2008	2008	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD, METRO 203	LOS ANGELES	CA	90048	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	1	12/18/2007	NEW	$397,500
														Subtotal = $397,500

Grand Total All Awards = $6,334,035

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Dectin-1 Signaling Mechanisms

Award Number: R01AI071116

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2008

PERIOD OF PERFORMANCE END DATE: 05/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer